1.  Capital Commitments
 
 Estimated amount of Contracts remaining to be executed on Capital
 Account (Net of Advances) Rs. 1,021.43 million (Previous year Rs. 1,235.14
 million) [Advances Rs. 83.82 million (Previous year Rs. 115.25 million)].
 
 2.  Contingent liabilities
 
 a) Claims/Demands for the following matters in respect of which
 proceedings or appeals are pending and are not acknowledged as debts :
 
                                              (Rs. in million)
 
 As at 31st March,                       2011        2010
 
 Central Excise                         50.85        32.27
 
 Customs                                14.14        40.69
 
 Sales Tax                              18.36        48.82
 
 Income Tax                            214.83       189.05
 
 Service Tax                            34.13        34.62
 
 Others                                 57.62       144.27
 
 Excluding demands in respect of business transferred to Jubilant
 Industries Limited in terms of the scheme of demerger though the
 demands may be continuing in the name of the Company.
 
 b) The Company has challenged the levy of transport fee by State of
 Maharashtra on consumption of rectifed spirit and molasses in the Nira
 factory. The order of State imposing the levy was stayed by the Hon''ble
 Mumbai High Court on 22nd October, 2001.  The Company has been advised
 that the levy of transport fee on rectifed spirit and molasses by State
 is not tenable. However, the Company has deposited Rs. 6.28 million under
 protest out of the total transport fee of Rs. 139.45 million which is
 shown as deposit in the financial statements.
 
 c) Outstanding guarantees furnished by Banks on behalf of the
 Company/by the Company including in respect of Letters of Credits is Rs.
 2,197.90 million (Previous year Rs. 2,605.60 million).
 
 d) Liability in respect of Bills discounted with Banks is Rs. 200 million
 (Previous year Rs. 850 million).
 
 e) The Company has given Corporate Guarantee on behalf of its
 subsidiaries, HSL Holdings Inc. & Draxis Pharma Inc. to ICICI Bank UK.
 PLC. & ICICI Bank, Canada for USD 50 million - effective guarantee as
 at 31st March, 2011 USD 18.75 million (Previous year USD 31.25 million)
 and USD 50.21 million respectively - total effective guarantee
 equivalent to Rs. 3,075.31 million (Previous year Rs. 3,657.59 million), to
 secure financial facility granted by them.
 
 f) Exports obligation undertaken by the Company under EPCG scheme to be
 completed over a period of fve/ eight years on account of import of
 Capital Goods at concessional import duty and remaining outstanding is
 Rs. 434.05 million (Previous year Rs. 434.05 million).  Similarly Export
 obligation under Advance License Scheme/DFIA scheme on duty free import
 of specifc raw materials, remaining outstanding is Rs. 2,363.44 million
 (Previous year Rs. 1,011.82 million).
 
 g) The Company has challenged before the Hon''ble Allahabad High Court,
 the increase in denaturing fee by the State of Uttar Pradesh w.e.f 1st
 April, 2004 on denaturing of rectifed spirit in the Gajraula factory
 and the writ petition has been admitted by the court. The Company has
 deposited Rs. 19.19 million under protest which is shown as deposits.
 
 h) Zila Panchayat at J.P. Nagar (in respect of the Company''s Gajraula
 plant) served a notice demanding a compensation of Rs. 277.40 million
 allegedly for, percolation of poisonous water stored in lagoons and
 flowing through the land of Zila Panchayat resulting in loss of crops
 and cattle of the farmers and for putting poisonous fy ash on national
 highway which caused loss to the health and damages to eyes and skin of
 people.
 
 District Magistrate issued a recovery certifcate along with 10%
 collection charges infating the demand to Rs. 305.14 million. In the
 opinion of the Company, the Zila Panchayat has no jurisdiction in
 raising this demand. The demand was challenged in Hon''ble Allahabad
 High Court and the court stayed the demand till further orders.
 
 i) The Company has challenged, before the Hon''ble Allahabad High Court,
 the levy of license fees of Rs. 2.87 million by State of Uttar Pradesh,
 for grant of PD-2 license for manufacture of Ethyl Alcohol for
 industrial use. The writ petition has been admitted and is being listed
 for fnal hearing. Though the amount has been deposited and shown as
 such, no provision against this has been made as the issue is covered
 by the earlier favorable judgment of the Hon''ble Supreme Court of
 India.
 
 j) The State of Uttar Pradesh (UP) has imposed levy on import of
 denatured spirit into the State of Uttar Pradesh (UP). The Company has
 imported denatured spirit into the State of Uttar Pradesh and has
 challenged levy amounting to Rs. 90 million before Hon''ble Allahabad High
 Court. The writ petition has been allowed by the High Court in favour
 of the Company. The State of Uttar Pradesh fled a Special Leave
 Petition (SLP) with Hon''ble Supreme Court. The SLP has been admitted
 but the Hon''ble Supreme Court has declined the request of the State of
 Uttar Pradesh (UP) to stay the operation of High Court Order.
 
 k) The Hon''ble Supreme Court has quashed the levy of license fee by
 State of Uttar Pradesh on captive consumption of denatured spirit in
 the Gajraula factory, and has ordered the refund of the fee paid during
 the period of dispute subject to condition that the amount has not been
 collected from the Company''s customers. Further the Court has directed
 the State to investigate whether the Company has collected the disputed
 fee from its customers to the extent bank guarantees were furnished.
 
 The Company is entitled to a refund of Rs. 84.06 million as the amount
 paid during the period of dispute or secured by bank guarantees was not
 collected from its customers. Accordingly the Company has approached
 the State of Uttar Pradesh for the refund of the said amount. The
 amount paid has been shown as deposit.
 
 3.  During the year a Scheme of Amalgamation and Demerger (Scheme)
 among Jubilant Life Sciences Ltd (formerly Jubilant Organosys Ltd),
 Speciality Molecules Ltd, Pace Marketing Specialities Ltd and Jubilant
 Industries Ltd (formerly Hitech Shiksha Ltd) became effective on 15th
 November, 2010. Under the Scheme, Speciality Molecules Limited (SML) a
 wholly owned subsidiary of Jubilant Life Sciences Ltd (Company) and
 Pace Marketing Specialties Limited (PMSL) an exclusive contract
 manufacturer of adhesives for Consumer Product Division of the JLL
 amalgamated with the Company on 31st March, 2010.  The Agri and
 Performance Polymer Businesses of the Company have been demerged into
 Jubilant Industries Limited (JIL) on 1st April, 2010. Adjustment on
 account of Demerger disclosed in the financial statements includes
 transactions between the appointed date and the effective date i.e.
 between 1st April, 2010 and 15th November, 2010.
 
 On amalgamation, shareholders of PMSL were issued 501,364 equity shares
 of the Company and the equity share capital of SML was cancelled as the
 same was held entirely by the Company. Upon Demerger, the shareholders
 of the Company received one equity share of Rs. 10 each of Jubilant
 Industries Limited for every 20 equity shares of Rs. 1 each held in the
 company.
 
 Effective, the Demerger appointed date, i.e. 1st April, 2010 till the
 scheme becoming effective, the operations of JIL were run by the
 company, for and on behalf of JIL, on trust and the economic Benefits
 attributable to JIL have been passed on to it, in terms of the said
 scheme. Since, the economic Benefits under the scheme have accrued from
 appointed date, the equity shares issued pursuant to the scheme have
 also been considered from the appointed date for the purpose of
 calculation of Earnings Per Share. Accordingly the results for the year
 are for the businesses remaining with the Company, post
 amalgamation/demerger, after giving the effect of the scheme and
 accordingly, not comparable with previous year.
 
 4.  The deferred tax liability is net of amount recoverable of Rs. 15.50
 million (Previous year Rs. 11.69 million) from the Employee Welfare Trust
 towards the tax chargeable on the income of trust on which the tax is
 payable by the Company.
 
 5.  Micro, Small and Medium Business Entities
 
 There are no Micro, Small & Medium Enterprises, to whom the Company
 owes dues, which are outstanding for more than 45 days as at 31st
 March, 2011. The information as required to be disclosed under the
 Micro, Small and Medium Enterprises Development Act, 2006 (MSMED) has
 been determined to the extent such parties have been identifed on the
 basis of information available with the Company.
 
 6.  Foreign Currency Convertible Bonds (FCCB)
 
 (A) FCCB – USD 75 million (FCCB 2010)
 
 The Company issued Zero Coupon Foreign Currency Convertible Bonds due
 2010 (FCCB 2010) for an aggregate value of USD 75 million, convertible
 at any time between 3rd July, 2005 to 14th May, 2010 by holders into
 fully paid equity shares of Rs. 1 each of the Company or Global
 Depositary Shares (GDSs) each representing one equity share of Rs. 1 each
 at an initial conversion price of Rs. 273.0648 per share with a fixed rate
 of exchange of Rs. 43.35 = USD 1. The conversion price was subject to
 adjustment in certain circumstances. The Bonds could also be redeemed,
 in whole but not in part, at the option of the Company at any time on
 or after 23rd May, 2008, subject to satisfaction of certain conditions.
 Unless previously converted, redeemed or purchased and cancelled, the
 Bonds were to be redeemed on 24th May, 2010 at 138.383% of their
 principal amount. The FCCBs were listed on Singapore Stock Exchange.
 The GDSs arising out of conversion of FCCBs were listed on Luxembourg
 Stock Exchange. Out of these FCCB 2010, USD 22.343 million were
 converted upto 31st March, 2009 into equity shares and this represented
 3,547,022 shares of Rs. 1 each as on 31st March, 2009 and USD 3 million
 Bonds were bought back at a discount and were cancelled. The balance
 bonds of USD 49.657 million outstanding were redeemed during the year.
 
 (B) FCCB – USD 200 million (FCCB 2011)
 
 The Company issued Zero Coupon Foreign Currency Convertible Bonds due
 2011 (FCCB 2011) for an aggregate value of USD 200 million, convertible
 at any time between 30th June, 2006 to 10th May, 2011 by holders into
 fully paid equity shares of Rs. 1 each of the Company or Global
 Depositary Shares (GDSs) each representing one equity share at an
 initial conversion price of Rs. 413.4498 per share with a fixed rate of
 exchange of Rs. 45.05 = USD 1. The conversion price is subject to
 adjustment in certain circumstances. The Bonds may also be redeemed, in
 whole but not in part, at the option of the Company at any time on or
 after 19th May, 2009, subject to satisfaction of certain conditions.
 Unless previously converted, redeemed or purchased and cancelled, the
 Bonds will be redeemed on 20th May, 2011 at 142.429% of their principal
 amount. The FCCBs are listed on Singapore Stock Exchange. The GDSs
 arising out of conversion of FCCBs are listed on Luxembourg Stock
 Exchange. Out of these FCCB 2011, USD 57.90 million Bonds were bought
 back at a discount and were cancelled. The balance bonds of USD 142.10
 million outstanding as of 31st March, 2011 are included under
 ''Unsecured Loans''.
 
 The proceeds of FCCB 2011 have been used for funding new projects – Rs.
 13.5 million (USD 0.30 million), investment in/acquisitions of overseas
 subsidiary companies - Rs. 8,873.0 million (USD 196.96 million) and issue
 expenses – Rs. 123.4 million (USD 2.74 million). There has been no
 conversion during the year in respect of the above FCCBs.
 
 Post demerger, the conversion price, for the outstanding FCCB''s
 amounting to USD 142.10 million has been reset to Rs. 379 per equity
 share of the company, based on valuation done by two independent
 Investment Bankers and has been intimated to the bondholders, as per
 the terms of the issue.
 
 The outstanding balance of FCCB 2011 - USD 142.10 million, on
 conversion would result in allotment of 16,890,778 equity shares of Rs. 1
 each.
 
 7. Employee Stock Option Scheme
 
 In terms of approval of shareholders accorded at the AGM held on 29th
 August, 2005 and in accordance with SEBI (ESOP & ESPS) Guidelines,
 1999, the Company instituted Jubilant Employees Stock Option Plan, 2005
 (Plan) for specifed categories of employees and directors of the
 Company and its Subsidiaries. Under the Plan as amended, upto 1,100,000
 Stock Options can be issued to eligible directors (other than promoter
 directors) and other specifed categories of employees of the Company/
 Subsidiaries. Options are to be granted at market price. As per SEBI
 Guidelines, the market price is taken as the closing price on the day
 preceding the date of grant of options, on the stock exchange where the
 trading volume is the highest.
 
 Each option, upon vesting, shall entitle the holder to acquire fve
 equity shares of Rs. 1 each. Options granted upto 28th August 2009 will
 vest entirely within two years from the grant date, with certain
 lock-in provisions. Options granted after 28th August 2009 will vest
 gradually over a period of 5 years from the grant date, without any
 lock-in provisions.
 
 The Company has constituted a Compensation Committee comprising of a
 majority of independent directors. This Committee is empowered to
 administer the Plan.
 
 In 2008-09, Jubilant Employees Welfare Trust was constituted for the
 purpose of acquisition of equity shares of the Company from the
 Secondary market or subscription of shares from the Company, to hold
 the shares and to allocate/transfer these shares to eligible employees
 of the Company from time to time on the terms and conditions specifed
 under the Plan. The members authorised grant of loan(s) from time to
 time to the Trust in one or more tranches, upto Rs. 1,000 million either
 free of interest or at interest agreed between the Board and the Trust.
 The outstanding loan to the Trust as at 31st March, 2011 is Rs. 269.90
 million (Previous year Rs. 423.21 million).
 
 During the year, the Company modifed the Plan to incorporate special
 provisions consequential to Scheme of Amalgamation & Demerger amongst
 the Company, Jubilant Industries Ltd. & others and to provide:
 
 (i) that an Option holder who is continuing with the Company, would be
 entitled to not only the equity shares of the Company but also the
 equity shares of Jubilant Industries Limited in accordance with the
 share exchange ratio i.e. One equity share of Rs. 10 each of Jubilant
 Industries Limited (JIL Share), free of cost, for every 20 equity
 shares of Rs. 1 each of the Company) when such options holder pays the
 exercise price in accordance with the Plan;
 
 (ii) that the Lock-in provisions, in accordance with the Plan, wherever
 applicable to the equity shares of the Company will also apply to the
 JIL Shares acquired by a Participant.
 
 (iii) for other specifc provisions applicable to Participant(s)
 transferred to Jubilant Industries Limited, including provision for
 accelerated vesting of Options on Effective Date, in case Options were
 granted at least one year before the Effective Date but not vested upto
 that date.
 
 Further, pursuant to the scheme, to the extent the Trust holds equity
 shares of the Company, equity shares of the Jubilant Industries Limited
 has been issued, in accordance with the share exchange ratio.
 
 Upto 31st March, 2011, the Trust has purchased 5,371,747 equity shares
 of the Company from the open market, out of interest free loan provided
 by the Company, out of which 1,530,010 shares were transferred to the
 employees on exercise of ESOPS. The Trust has also been issued 192,086
 JIL Shares in accordance with the Scheme.
 
 8. a) The Company''s significant operating lease arrangements are in
 respect of premises (residential, offces, godown etc.).  These leasing
 arrangements, which are cancelable, range between 11 months and 3 years
 generally and are usually renewable by mutual agreeable terms. The
 aggregate lease rentals payable are charged as expenses.
 
 b) The Company has significant operating lease arrangement in respect of
 lease of land which are non-cancellable for a fixed period of 25 years.
 These lease rentals are subject to escalation whereby the Lessor is
 entitled to increase the Lease Rental by 10% of the average lease
 rental of preceding three years (blocked period).
 
 9.  In line with the applicable Accounting Standards, during the year,
 interest amounting to Rs. 202.24 million (Previous Year Rs. 69.65 million)
 and expenditure incurred on start up and commissioning of the project
 and /or substantial expansion, including the expenditure incurred on
 test runs and Trial Runs (Net of trial run receipts, if any) up to the
 date of commencement of commercial production amounting to Rs. 197.87
 million (Previous Year Rs. 188.56 million) have been capitalised. The
 said expenditure (net of trial run receipts), so capitalised are
 accumulated as Capital work in progress.
 
 10.  The carrying value of internally generated Intangible Asset –
 Product Development including product development under progress is
 reviewed for impairment annually. Accordingly a sum of Rs. 91.61 million
 (Previous Year Rs. 62.63 million) has been written off during the year.
 
 11. (A) Deferred Tax Assets and Liabilities are attributable to the
 following items:
 
 (B) The Profit attributable to the operations under the (EOU) Export
 Oriented Units Scheme are deductible from taxable income for the year
 ended 2010- 11 and accordingly income from EOU setup at Nanjangud,
 Mysore, at Bhartiagram, Jyotiba Phoolay Nagar (Gajraula), Uttar Pradesh
 and at Ambernath, Maharashtra have been considered as tax deductible,
 and provision for tax is made accordingly.
 
 (C) Current Tax includes Rs. 32.70 million related to previous year
 including interest thereon.
 
 12. The bottling unit of the Company situated at Nira holds a potable
 liquor license for Indian Made Foreign Liquor (IMFL) and the same is
 bottling IMFL on the order of another Company and is charging bottling
 fee. The Accounts recognise Revenue and Expenditure only to the extent
 the Company enjoys benefcial interest. In Compliance with the
 requirements of Schedule VI to the Companies Act, 1956, the following
 information is given hereunder in respect of the transactions where the
 Company does not enjoy benefcial interest:
 
 13.  The Company has opted for accounting the exchange difference
 arising on reporting of long term foreign currency monetary items in
 line with the Companies (Accounting Standards) Amendment Rules 2009 on
 Accounting Standard 11 (AS-11) – The Effects of Changes in Foreign
 Exchange Rates notifed by the Ministry of Corporate Affairs on 31st
 March, 2009. Accordingly during 2008-09 the Company had capitalized
 exchange difference amounting to Rs. 1,130.81 million to the cost of fixed
 assets and Rs. 1,596.03 million to foreign currency monetary item
 translation difference account (FCMITDA) including reversal of exchange
 gain amounting to Rs. 1,030.57 million credited to Profit & Loss Account
 in the 2007-08. During the year Rs. 161.30 million (Previous Year Rs.
 1,436.57 millions) were reversed from the FCMITDA on account of
 exchange difference. Balance Rs. 102.68 million in the FCMITDA has been
 credited to Profit & Loss Account as required in terms of the said
 notifcation.
 
 14.  The Company uses derivative financial instruments such as forward
 contracts to selectively hedge its currency exposures, frm commitments
 and highly probable forecast transactions, denominated in USD and EURO.
 Usually, the forward contracts mature within two years. The Company
 actively manages its currency/interest rate exposures on loans through
 a centralised treasury setup and uses derivatives such as currency
 swaps and interest rate swaps to mitigate the risk from such exposures.
 
 15. Employee Benefits has been calculated as under: (A) Defned
 Contribution Plans
 
 a.  Provident Fund*
 
 b.  Superannuation Fund
 
 (B) Defned Beneft Plans
 
 i.  Compensated Absences and Gratuity
 
 In accordance with Accounting Standard 15(AS 15) - Employee Benefits
 (Revised 2005), an actuarial valuation has been carried out in respect
 of gratuity and compensated absences. The discount rate assumed is 8.35
 % which is determined by reference to market yield at the Balance Sheet
 date on Government bonds. The retirement age has been considered at 58
 years and mortality table is as per LIC (1994-96).
 
 The estimates of future salary increases, considered in actuarial
 valuation, 10% for frst year and 6% thereafter, take account of
 infation, seniority, promotion and other relevant factors, such as
 supply and demand in the employment market.
 
 ii.  Provident Fund:
 
 The Guidance on implementation of AS 15, Employee Benefits (Revised
 2005) issued by Accounting Standard Board (ASB) states that Benefits
 involving provident funds, which require interest shortfall to be
 compensated, are to be considered as defned beneft plans. The actuary
 has recommended a provision of Rs. 6.74 million towards liability likely
 to arise towards interest guarantee. The trust is managing common
 corpus of three companies. The total liability of Rs. 6.74 million as
 worked out by the actuary has been allocated to each entity based on
 the corpus value of each entity as on 31st March, 2011. Accordingly Rs.
 5.81 million has been charged to Profit & Loss Account during the year.
 The Company has contributed Rs. 77.48 million to Provident Fund (Previous
 Year Rs. 68.38 million) for the year.
 
 16. Segment Reporting :
 
 i) Based on the guiding principles given in Accounting Standard 17
 (AS-17) on Segment Reporting, the Company''s Primary Business Segments
 were organized around customers on industry and product lines as under,
 however, Post demerger of Agri & Performance Polymers Businesses the
 Company has identifed only one segment-PLSPS as reportable segment.
 
 a.  Pharmaceuticals and Life Sciences Products & Services (PLSPS) : i)
 Custom Research & Manufacturing Services (CRAMS)-Proprietary Products
 and Exclusive Synthesis, Active Pharmaceuticals Ingredients (APIs) ii)
 Pharmaceutical Products- Generics iii) Life Sciences Chemicals-Acetyls
 iv) Nutrition Ingredients-Nutrition ingredients for Pharma, Human and
 Animal applications.
 
 b.  Agri & Performance Polymers(APP) : i) Agri Products-SSP, Agro
 Chemicals ii) Performance Polymers-Consumer Products, Application
 Polymers, Food Polymers, Latex and other products.
 
 ii) In respect of Secondary Segment information, the Company has
 identifed its Geographical segments as:
 
 (i) Within India (ii) Outside India.
 
 iii) Inter Segment Transfer Pricing
 
 Inter Segment Transfer prices are based on market prices.
 
 21. A.  Related Party Disclosures
 
 1.  Related parties where control exists:
 
 a) Subsidiaries including Step-down subsidiaries:
 
 Jubilant First Trust Healthcare Ltd., Asia Healthcare Development Ltd.,
 Jubilant Infrastructure Ltd., Jubilant Pharma Pte. Ltd., Cadista
 Holdings Inc., Jubilant Cadista Pharmaceuticals Inc. (formerly Cadista
 Pharmaceuticals Inc.), Colvant Sciences, Inc. (Dissolved wef 31st
 March, 2011), Jubilant Life Sciences (Shanghai) Ltd. (formerly Jubilant
 Organosys (Shanghai) Ltd.), Jubilant Life Sciences International Pte.
 Ltd. (formerly Jubilant Organosys International Pte. Ltd.), Draximage
 Ltd., Cyprus, Draximage Ltd., Ireland, Draximage LLC, Jubilant
 DraxImage (USA) Inc. (formerly DSPI Inc., USA), Deprenyl Inc., USA,
 Jubilant DraxImage Ltd. (formerly Draximage India Ltd.), Jubilant
 DraxImage Inc.  (formerly Draxis Specialty Pharmaceuticals Inc.),
 6963196 Canada Inc., 6981364 Canada Inc., DAHI LLC. (Dissolved wef 21st
 March 2011), DAHI Animal Health (UK) Ltd., Draximage (UK) Ltd.,
 Jubilant Life Sciences (BVI) Ltd. (formerly Jubilant Organosys (BVI)
 Ltd.), Jubilant Biosys (BVI) Ltd., Jubilant Drug Development Pte. Ltd.,
 Jubilant Chemsys Ltd., Jubilant Clinsys Ltd. (formerly Clinsys Clinical
 Research Ltd.), Jubilant Innovation (BVI) Ltd., Jubilant Innovation
 Pte. Ltd., Jubilant Life Sciences (Switzerland) AG, Schaffhausen,
 Jubilant Pharma NV, Jubilant Pharmaceuticals NV, PSI Supply NV,
 Jubilant Life Sciences Holdings Inc. (formerly Clinsys Holdings, Inc.),
 Jubilant Clinsys Inc. (formerly Clinsys Clinical Research, Inc.), HSL
 Holdings Inc., Jubilant HollisterStier LLC (formerly Hollister-Stier
 Laboratories LLC), Draxis Pharma Inc., Draxis Pharma LLC, Generic
 Pharmaceuticals Holdings, Inc., Jubilant Life Sciences (USA) Inc.
 (formerly Jubilant Organosys (USA) Inc.), Jubilant Innovation (India)
 Ltd., Jubilant Innovation (USA) Inc., Jubilant Biosys (Singapore) Pte.
 Ltd., Jubilant Biosys Ltd., Jubilant Discovery Services, Inc., Cadista
 Pharmaceuticals (UK) Limited (Dissolved on 13th April, 2010).
 
 b) Other Entities:
 
 Draxis Pharma General Partnership Canada, Draximage General Partnership
 Canada, Vanthys Pharmaceutical Development Pvt. Ltd (50:50 Joint
 Venture between Jubilant Innovation Pte. Ltd. and Eli Lilly & Co )
 
 2.  Other Related parties with whom transactions have taken place
 during the year.
 
 a) Enterprise over which certain Key Management Personnel have
 significant infuence:
 
 Jubilant Enpro Pvt. Ltd., Jubilant Oil & Gas Pvt. Ltd., Jubilant
 Foodworks Ltd., Tower Promoters Pvt. Ltd., Focus Brands Trading (India)
 Pvt. Ltd., B &M Hot Breads Pvt. Ltd, Jubilant Industries Ltd.
 
 b) Key Management Personnel:
 
 Mr. Shyam S. Bhartia, Mr. Hari S. Bhartia, Mr. Shyamsundar Bang, Dr. J.
 M. Khanna, Mr. R. Sankaraiah, Mr. Pramod Yadav, Mr. Rajesh Srivastava,
 Mr. Neeraj Agarwal, Mr. Chandan Singh.
 
 c) Relatives of Key Management Personnel:
 
 Ms. Asha Khanna (wife of Dr. J. M. Khanna), Ms. Shobha Bang (wife of
 Mr. Shyamsundar Bang).
 
 d) Others:
 
 Vam Employees Provident Fund Trust, Jubilant Employee Welfare Trust ,
 Jubilant Bhartia Foundation, Vam Officers Superannuation Fund, Amarchand
 & Mangaldas & Suresh A. Shroff & Co.
 
 17. B.  Promoter Group
 
 Group companies
 
 The Company is controlled by Mr.Shyam S Bhartia/Mr. Hari S Bhartia
 group (the promoter group), being a group as defned in the Monopolies
 and Restrictive Trade Practices Act, 1969.
 
 The persons constituting the promoter group include individuals and
 corporate bodies who/which jointly exercise, and are in a position to
 exercise, control over the Company. The names of these individuals and
 bodies corporate are Mr. Shyam S Bhartia, Mr. Hari S Bhartia, Mrs.
 Shobhana Bhartia, Mrs. Kavita Bhartia, Mr.Priyavrat Bhartia, Mr.Shamit
 Bhartia, Ms.  Aashti Bhartia, Master Arjun S Bhartia, Mrs. Namrata
 Bhartia, Master Agastya Bhartia, Enpro Exports Private Ltd., Jaytee
 Private Ltd., Jubilant Enpro Private Ltd., Jubilant Securities Private
 Ltd., Jubilant Capital Private Ltd., Rance Investment Holdings Ltd.,
 Cumin Investments Ltd., Torino Overseas Ltd., Vam Holdings Ltd., Nikita
 Resources Private Ltd., Jubilant Oil & Gas Pvt. Ltd., Enpro Oil Pvt
 Ltd, Tower Promoters Pvt. Ltd, U C Gas & Engineering Ltd., Western
 Drilling Contractors Pvt. Ltd, Jubilant Realty Pvt. Ltd, Jubilant
 Properties Pvt. Ltd., Indian Country Homes Pvt. Ltd., Jubilant E& P
 Ventures Pvt. Ltd, Jubilant Retail Pvt. Ltd., Jubilant Stock Holding
 Pvt. Ltd. (formerly Jubilant Retail Holding Pvt. Ltd.), Jubilant
 Motorworks Pvt. Ltd. (formerly Jubilant Motors Pvt. Ltd.), Jubilant
 Retail Consolidated Pvt. Ltd., B &M Hot Breads Pvt.  Ltd.
 
 18. (A) Capacities and Production: The ministry of Corporate Affairs,
 Government of India vide its General Notifcation No.  S.O.301(E) dated
 8th February 2011 issued under Section 211(3) of the Companies Act,
 1956 has exempted certain classes of companies from disclosing certain
 information in their Profit & Loss Account. The Company being an ''export
 oriented company'' is entitled to the exemption. The Board has given its
 consent with regards to Non-disclosure of information in terms of said
 Notifcation.
 
 Accordingly, disclosures mandated by paragraphs 3(i)(a), 3(ii)(a),
 3(ii)(b) and 3(ii)(d) of Part II, Schedule VI to the Companies Act,
 1956 have not been provided.
 
 19. Previous Year''s figures have been regrouped/rearranged wherever
 considered necessary to conform to this year''s classification. (Also
 Refer Note 4 of Schedule N).